Old drug, new hope: niclosamide combo targets resistant prostate cancer
NCT ID NCT07683013
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This early-stage trial tests whether adding CP-PCA07 (a form of niclosamide, a drug used for tapeworm infections) to the standard drug enzalutamide can safely help men with castration-resistant prostate cancer that has stopped responding to treatment. The study involves 18 men and aims to find the best dose and check for side effects, while also measuring changes in PSA levels and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CP-PCA07 (niclosamide) combined with enzalutamide
- What this could lead to
- If successful, this combination could offer a new treatment option for men with castration-resistant prostate cancer who have stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 18 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom-Made vaccine takes on tough prostate cancer
- New drug IDE574 enters human trials for Hard-to-Treat cancers
- Engineered immune cells injected directly into prostate tumors: a new hope?
- Experimental cancer drug DCC-3084 tested in early trial
- New imaging agent aims to light up Hard-to-Find cancers
- Radioactive antibody targets Hard-to-Treat cancers in early trial